KRON Delists as Concentra Completes $0.57 Cash-and-CVR Tender Offer

Rhea-AI Filing Summary

Kronos Bio, Inc. (KRON) has confirmed the successful completion of its sale to Concentra Biosciences, LLC. Amendment No. 2 to the company’s Schedule 14D-9 discloses the final tender-offer results and closing of the downstream merger executed under Section 251(h) of the Delaware General Corporation Law.

The cash-and-CVR offer of $0.57 per share plus one non-transferable contingent value right (CVR) expired at 12:00 a.m. ET on 19 Jun 2025. Broadridge, acting as depositary, reported that 44,503,838 shares—approximately 72.90 % of outstanding stock—were validly tendered and not withdrawn, satisfying the minimum-tender condition and all other offer requirements.

Immediately after expiration, Concentra’s subsidiary accepted and will promptly pay for all tendered shares. Owning more than the statutory threshold, the buyer consummated the short-form merger on 20 Jun 2025 without a shareholder vote. Each remaining share (other than treasury shares and properly perfected appraisal shares) was automatically cancelled and converted into the right to receive the same offer price, subject to withholding taxes.

Trading in KRON shares ceased prior to the Nasdaq open on 20 Jun 2025. The company will be delisted from Nasdaq and its common stock will be deregistered under the Securities Exchange Act of 1934, ending Kronos Bio’s status as a public company.

Positive

• 72.90 % of shares tendered, satisfying the minimum condition and enabling swift deal closure.
• Shareholders to receive $0.57 in cash plus one CVR per share, providing immediate liquidity and potential contingent upside.
• All regulatory and contractual conditions met; transaction closed on schedule without the need for a shareholder vote.

Negative

• KRON shares ceased trading and will be delisted from Nasdaq, removing public liquidity.
• CVRs are non-transferable, limiting holders’ ability to monetise future contingent payments.

Insights

M&A Specialist

TL;DR: Tender reached 72.9%, enabling 251(h) short-form merger; deal closed, cash & CVR paid, KRON delists.

The acceptance rate comfortably cleared the minimum-tender threshold, allowing Concentra to close without further extensions. Cash consideration of $0.57 plus the CVR is now contractually due to all former holders. Regulatory and contractual hurdles are reported as satisfied or waived—no remaining execution risk. Delisting and deregistration eliminate ongoing disclosure costs for the acquirer and mark the end of public equity optionality for prior investors. From an M&A standpoint, the process adhered to the expected timeline and statutory mechanics, signalling efficient execution.

Portfolio Manager

TL;DR: Transaction final; shareholders receive cash exit, but future upside shifts to private ownership.

Investors now have certainty of proceeds and timing, reducing any lingering arbitrage spread. The CVR element provides contingent participation in predefined milestones, yet remains non-transferable, limiting post-close liquidity. Delisting eliminates future valuation volatility but also forecloses participation in any operational turnaround. Overall impact skews positive for risk-arbitrage holders seeking quick monetisation, neutral-to-negative for long-term biotech investors who preferred public exposure.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

______________________

SCHEDULE 14D-9
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
(Amendment No. 2)

______________________

Kronos Bio, Inc.
(Name of Subject Company)

______________________

Kronos Bio, Inc.
(Name of Persons Filing Statement)

______________________

Common Stock, $0.001 par value per share
(Title of Class of Securities)

50107A104
(CUSIP Number of Class of Securities)

______________________

Deborah Knobelman, Ph.D.
President, Interim Chief Executive Officer, Chief Financial Officer and Chief Operating Officer
Kronos Bio, Inc.
301 Binney Street, 2nd Floor East
Cambridge, MA
(650) 781-5200
(Name, address, and telephone number of person authorized to receive notices and communications
on behalf of the persons filing statement)

______________________

With a copy to:
Michael R. Patrone, Esq.
Amanda J. Gill, Esq.
Goodwin Procter LLP
New York Times Bldg
620 8th Ave
New York, NY 10018
(212) 813-8800

______________________

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Amendment No. 2 (this “Amendment”) to Schedule 14D-9 amends and supplements the Schedule 14D-9 previously filed by Kronos Bio, Inc., a Delaware corporation (“Kronos” or the “Company”) with the U.S. Securities and Exchange Commission on May 15, 2025 (as amended or supplemented by Amendment No. 1 to Schedule 14D-9 on June 5, 2025 and as may be further amended and supplemented from time to time, the “Schedule 14D-9”), with respect to the tender offer made by Concentra Merger Sub IV, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), to purchase all of the issued and outstanding shares of Kronos’ common stock, par value $0.001 per share (the “Shares”), for (i) $0.57 per Share in cash (the “Cash Amount”) plus (ii) one non-transferable contractual contingent value right per Share (a “CVR,” and each CVR together with the Cash Amount, the “Offer Price”), all upon the terms and subject to the conditions as set forth in the Offer to Purchase, dated May 15, 2025 (as amended or supplemented from time to time, the “Offer to Purchase”), and in the related Letter of Transmittal (as amended or supplemented from time to time, the “Letter of Transmittal,” which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, constitute the “Offer”).

The Offer is described in a Tender Offer Statement filed under cover of Schedule TO with the SEC on May 15, 2025, by Parent and Purchaser (as amended and supplemented on June 5, 2025 and as may be further amended or supplemented from time to time).

Capitalized terms used in this Amendment but not defined herein shall have the respective meaning given to such terms in the Schedule 14D-9. The information set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference, except that such information is hereby amended or supplemented to the extent specifically provided herein. This Amendment is being filed to disclose certain updates as reflected below.

ITEM 8.    ADDITIONAL INFORMATION

Item 8 of the Schedule 14D-9 is hereby amended and supplemented by adding, immediately after the subsection titled “— Regulatory Approvals,” the following new subsection:

“Final Results of the Offer and Completion of the Merger

The Offer and related withdrawal rights expired at one minute after 11:59 p.m., Eastern time, on June 18, 2025 and were not further extended. Broadridge Corporate Issuer Solutions, LLC, the depositary and paying agent for the Offer, advised Purchaser that, as of the expiration of the Offer, a total of 44,503,838 Shares were validly tendered and not validly withdrawn, representing approximately 72.90% of the Shares outstanding as of the expiration of the Offer.

As of the expiration of the Offer, the number of Shares validly tendered in accordance with the terms of the Offer and not validly withdrawn satisfied the Minimum Tender Condition (as defined in the Merger Agreement), and all other conditions to the Offer were satisfied or waived. Immediately after the expiration of the Offer, Purchaser irrevocably accepted for payment all Shares validly tendered and not validly withdrawn, and expects to promptly pay for such Shares pursuant to the terms of the Offer and the Merger Agreement.

As a result of its acceptance of the Shares tendered pursuant to the Offer and in accordance with Section 251(h) of the DGCL, Purchaser owns a number of Shares that is greater than the percentage of Shares that would be required to adopt the Merger Agreement by a vote of Kronos’ stockholders. Accordingly, pursuant to the Merger Agreement, Parent and Purchaser completed the acquisition of Kronos on June 20, 2025 by consummating the Merger pursuant to the Merger Agreement without a vote of Kronos’ stockholders in accordance with Section 251(h) of the DGCL. At the Effective Time, each outstanding Share (other than (i) Shares held in the treasury of Kronos immediately prior to the Effective Time, which will be canceled without any conversion thereof and no consideration will be delivered in exchange therefor, (ii) any Shares held by stockholders or owned by beneficial owners who are entitled to demand, and have properly demanded, appraisal of such Shares in accordance with the DGCL, and have neither failed to perfect nor effectively withdrawn or lost such rights prior to the Effective Time and (iii) Shares that were owned by Parent, Purchaser or any other subsidiary of Parent at the commencement of the Offer and is owned by Parent, Purchaser or any other subsidiary of Parent immediately prior to the Effective Time) was cancelled and converted into the right to receive the Offer Price, without interest and in each case, less any applicable withholding taxes, from Purchaser.

Prior to the opening of trading on the Nasdaq Stock Market LLC (“Nasdaq”) on June 20, 2025, all Shares ceased trading, and following the consummation of the Merger, all Shares will be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.”

1

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 20, 2025

		Kronos Bio, Inc.
		By:		/s/ Deborah Knobelman
				Deborah Knobelman, Ph.D
				President, Interim Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

2

FAQ

What percentage of Kronos Bio (KRON) shares were tendered?

Approximately 72.90 % (44,503,838 shares) were validly tendered and not withdrawn.

What is the consideration paid in the Concentra tender offer for KRON?

Each share receives $0.57 in cash plus one non-transferable CVR, subject to withholding taxes.

When did the tender offer for Kronos Bio expire?

The offer expired at one minute after 11:59 p.m. ET on 18 Jun 2025.

When was the merger with Concentra completed?

The short-form merger closed on 20 Jun 2025 under DGCL Section 251(h).

Will KRON shares continue to trade on Nasdaq after the merger?

No. Trading ceased before the 20 Jun 2025 market open; the shares will be delisted and deregistered.